A Phase 1 Dose-Escalation Study in Adults With Severe IgE-Mediated Food Allergy, to Assess the Safety, Tolerability, and Pharmacodynamic Effects of Short-Term Linvoseltamab Treatment, A BCMAxCD3 Bispecific Antibody to Induce T-Cell Killing of IgE Producing Plasma Cells, on Top of Chronic Dupilumab Treatment, to Prevent the Formation of New IgE Producing Plasma Cells

R5458-668-ALG-2219

This study is researching an experimental drug called linvoseltamab when combined with another drug called dupilumab. The study is focused on patients who have IgE-mediated food allergy. If the patient has an allergy, the immune system overreacts to an allergen (eg, certain foods such as peanuts, milk, shellfish) by producing antibodies called IgE. IgE antibodies are released by cells such as plasma cells. These antibodies and allergen bind to other cells that release chemicals, causing an allergic reaction. The aim of the study is to see how safe and tolerable linvoseltamab is when combined with dupilumab. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * Whether linvoseltamab when combined with dupilumab has an effect on other types of antibodies in the blood at different times * How much study drug(s) is in the blood at different times

2024-05-06

2026-04-24

2026-04-24

Recruiting

Early phase I

6

Key Inclusion Criteria: 1. Clinical history of documented, ongoing, severe IgE-mediated allergy to food (peanut, hazelnut, walnut, cashew, milk, egg/egg white, soy, wheat, sesame, cod, salmon, tuna, lobster, crab and/or shrimp; documented symptom\[s\] of anaphylaxis due to exposure) 2. History of physician reported anaphylaxis to food requiring epinephrine administration and/or requiring an emergency visit or inpatient hospitalization 3. Must be receiving DUPIXENT as standard of care for the treatment of atopic dermatitis (AD) for a minimum of 12 weeks prior to screening, or willing to initiate dupilumab treatment and must agree to remain on dupilumab for the duration of the study treatment period 4. Participant must be willing to use an epinephrine auto-injector device 5. Participant must be willing to receive booster and/or re-vaccination(s), including for live (attenuated) vaccinations, based on results of vaccine antibody titers and investigator opinion 6. Has a body mass index between 18 and 32 kilogram per square metre (kg/m2), inclusive Key Exclusion Criteria: 1. Pregnant or breastfeeding women 2. History of chronic disease (other than AD) requiring therapy (eg, heart disease, diabetes, hypertension) that, in the opinion of the principal investigator, would represent a risk to the participant's health or safety in this study or the participant's ability to comply with the study protocol. Participants on DUPIXENT for conditions other than AD (eg, asthma, eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps, prurigo nodularis, etc) are excluded. 3. History of progressive multifocal leukoencephalopathy, neurodegenerative condition, central nervous system (CNS) movement disorder, or patients with a history of seizure within 12 months prior to Day 1 4. Recent history (within past 30 days) of a grade 3 or grade 4 gastrointestinal bleed, history of inflammatory bowel disease or severe diverticulitis or previous gastrointestinal perforation 5. History of moderate or severe asthma based on the Global Initiative for Asthma (GINA) guidelines 6. Pre-bronchodilator forced expiratory volume in the first second (FEV1) \<80% of predicted using local reference values 7. Any prior exposure to a B-cell maturation antigen (BCMA) targeted therapy 8. Use of systemic corticosteroids within 2 months prior to screening 9. Use of other forms of allergen immunotherapy (eg, oral, SC, patch, or sublingual) or immunomodulatory therapy (not including corticosteroids) within 6 months prior to screening 10. Unwilling to discontinue use of antihistamines within 5 days prior to screening and within 5 days prior to skin prick test (SPT) 11. Hypersensitivity to epinephrine and any of the excipients in the epinephrine product 12. Within the previous 2 months of the screening visit has a history of bacterial, protozoal, viral or parasite infection requiring hospitalization or treatment with IV anti-infectives 13. Known history of human immunodeficiency virus (HIV) infection or HIV seropositivity at the screening visit NOTE: Other protocol-defined inclusion/exclusion criteria apply

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 6, 'type': 'ESTIMATED'}}

2024-04-30